{"success":true,"data":{"pressRelease":{"id":"164906","rtpr_id":"nGNE3VP1b-20261008","ticker":"CHEMM","exchange":"Nasdaq Copenhagen","all_tickers":["CHEMM"],"title":"REG-Initiation of buy-back programme","author":"Globe Newswire","published_at":"2026-10-08T20:33:50.055Z","article_body":"ANNOUNCEMENT NO. 320\n\n8 October 2026\n\n\n\nThe Board of Directors of ChemoMetec A/S has decided to buy back own shares\nbased on the authorisation granted at the Annual General Meeting on 8 October\n2026. The authorisation is valid until the next Annual General Meeting, which\nwill be held on 7 October 2027 and covers up to 10% of the share capital.\n\nAt the start of the share buy-back programme, ChemoMetec A/S own 239.950\nshares. The purpose of the share buy-back programme is to adjust the company's\ncapital structure.\n\nThe share buy-back programme runs from 12 October 2026 up to and including 5\nMarch 2027.\n\nThe share buy-back programme is carried out without the application of the\nSafe Harbour rules in Article 5 of the Market Abuse Regulation. The buy-back\nis carried out at market price and in accordance with the authorisation\ngranted by the general meeting and within the framework of the rules of the\nMarket Abuse Regulation.\n\nTo ensure that the trades are carried out on arm's length terms, Danske Bank\nA/S (lead manager) will be responsible for all trades under the share buy-back\nprogramme. Danske Bank A/S has also been given a discretionary mandate to\ninvestigate and potentially acquire shares from major shareholders (block\ntrades).\n\nUnder this agreement, Danske Bank A/S will make its trading decisions\nindependently of and without the influence of ChemoMetec A/S and within the\nfollowing framework:\n* A maximum of 500,000 shares may be repurchased, corresponding to 2.9% of the\nshare capital.\n* The maximum consideration that ChemoMetec A/S may pay for shares purchased\nunder the programme is DKK 100 million.\nAdditional Information\n\nMartin Helbo Behrens, CEO\nTel.: (+45) 81 10 06 80 \n\nPhillip Massie Price, CFO\nTel.: (+45) 81 10 06 80 \n\n\n\nAbout ChemoMetec A/S\n\nChemoMetec develops, manufactures and markets instruments for cell counting\nand a wide range of other measurements. ChemoMetec’s instruments are\nmarketed to the pharmaceutical, biotech and agricultural industries worldwide.\nChemoMetec’s customers include some of the world’s leading pharmaceutical\ncompanies.\n\nChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For\nfurther information, go to www.chemometec.com.\n\nAttachment\n*     Initiation of buy-back programme\n(https://ml-eu.globenewswire.com/Resource/Download/0fec9adc-2063-470c-9c18-0afd85b73b76)","article_body_html":"","raw_payload":{"data":{"id":"nGNE3VP1b-20261008","title":"REG-Initiation of buy-back programme","author":"Globe Newswire","ticker":"CHEMM","created":"2026-10-08T20:33:50.055Z","tickers":["CHEMM"],"exchange":"Nasdaq Copenhagen","article_body":"ANNOUNCEMENT NO. 320\n\n8 October 2026\n\n\n\nThe Board of Directors of ChemoMetec A/S has decided to buy back own shares\nbased on the authorisation granted at the Annual General Meeting on 8 October\n2026. The authorisation is valid until the next Annual General Meeting, which\nwill be held on 7 October 2027 and covers up to 10% of the share capital.\n\nAt the start of the share buy-back programme, ChemoMetec A/S own 239.950\nshares. The purpose of the share buy-back programme is to adjust the company's\ncapital structure.\n\nThe share buy-back programme runs from 12 October 2026 up to and including 5\nMarch 2027.\n\nThe share buy-back programme is carried out without the application of the\nSafe Harbour rules in Article 5 of the Market Abuse Regulation. The buy-back\nis carried out at market price and in accordance with the authorisation\ngranted by the general meeting and within the framework of the rules of the\nMarket Abuse Regulation.\n\nTo ensure that the trades are carried out on arm's length terms, Danske Bank\nA/S (lead manager) will be responsible for all trades under the share buy-back\nprogramme. Danske Bank A/S has also been given a discretionary mandate to\ninvestigate and potentially acquire shares from major shareholders (block\ntrades).\n\nUnder this agreement, Danske Bank A/S will make its trading decisions\nindependently of and without the influence of ChemoMetec A/S and within the\nfollowing framework:\n* A maximum of 500,000 shares may be repurchased, corresponding to 2.9% of the\nshare capital.\n* The maximum consideration that ChemoMetec A/S may pay for shares purchased\nunder the programme is DKK 100 million.\nAdditional Information\n\nMartin Helbo Behrens, CEO\nTel.: (+45) 81 10 06 80 \n\nPhillip Massie Price, CFO\nTel.: (+45) 81 10 06 80 \n\n\n\nAbout ChemoMetec A/S\n\nChemoMetec develops, manufactures and markets instruments for cell counting\nand a wide range of other measurements. ChemoMetec’s instruments are\nmarketed to the pharmaceutical, biotech and agricultural industries worldwide.\nChemoMetec’s customers include some of the world’s leading pharmaceutical\ncompanies.\n\nChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For\nfurther information, go to www.chemometec.com.\n\nAttachment\n*     Initiation of buy-back programme\n(https://ml-eu.globenewswire.com/Resource/Download/0fec9adc-2063-470c-9c18-0afd85b73b76)"},"type":"article","timestamp":"2026-10-08T20:33:50.1477319Z","server_sent_at_ms":1791491630147},"received_at":"2026-10-08T20:33:50.199Z","source_url":null},"analysis":{"id":"153310","press_release_id":"164906","analysis_json":{"industry":{"label":"Electronic Equipment, Instruments & Components","sector":"Information Technology"},"redFlags":[],"eventType":"buyback","narrative":"ChemoMetec's board initiated a share buy-back programme running from 12 October 2026 through 5 March 2027, executed by Danske Bank A/S at market price.\n\nThe programme allows repurchase of up to 500,000 shares (2.9% of share capital) for a maximum DKK 100 million, with Danske Bank also mandated to explore block trades from major shareholders.\n\nThe stated purpose is adjusting the capital structure, backed by a fresh AGM authorisation covering up to 10% of share capital.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"DKK 100M buy-back (2.9% of shares) signals capital-structure tightening at ChemoMetec."},"keyFigures":{"customDimensions":{"program_end":"2027-03-05","max_share_pct":"2.9%","program_start":"2026-10-12","authorization_cap":"10% of share capital","max_consideration":"DKK 100 million","max_shares_repurchase":500000,"shares_owned_at_start":239950}},"namedEntities":{"people":[{"name":"Martin Helbo Behrens","role":"CEO"},{"name":"Phillip Massie Price","role":"CFO"}],"products":[],"companies":[{"name":"ChemoMetec A/S","ticker":"CHEMM"},{"name":"Danske Bank A/S","relationship":"lead manager"}],"dollarAmounts":[{"amount":"DKK 100 million","context":"maximum consideration for share buy-back programme"}]},"materialImpact":{"score":3,"reasoning":"Board-approved buy-back of up to 500,000 shares (~2.9% of share capital) for up to DKK 100 million, running Oct 2026 to Mar 2027. A routine but real capital-return signal for a mid-cap, not market-moving."},"tickerRelevance":{"others":[],"primary":"CHEMM"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap European life-science instruments","programSize":"DKK 100M / 2.9% of share capital","eventGravity":"routine buyback initiation"}},"event_type":"buyback","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"ChemoMetec's board initiated a share buy-back programme running from 12 October 2026 through 5 March 2027, executed by Danske Bank A/S at market price.\n\nThe programme allows repurchase of up to 500,000 shares (2.9% of share capital) for a maximum DKK 100 million, with Danske Bank also mandated to explore block trades from major shareholders.\n\nThe stated purpose is adjusting the capital structure, backed by a fresh AGM authorisation covering up to 10% of share capital.","key_figures":{"customDimensions":{"program_end":"2027-03-05","max_share_pct":"2.9%","program_start":"2026-10-12","authorization_cap":"10% of share capital","max_consideration":"DKK 100 million","max_shares_repurchase":500000,"shares_owned_at_start":239950}},"named_entities":{"people":[{"name":"Martin Helbo Behrens","role":"CEO"},{"name":"Phillip Massie Price","role":"CFO"}],"products":[],"companies":[{"name":"ChemoMetec A/S","ticker":"CHEMM"},{"name":"Danske Bank A/S","relationship":"lead manager"}],"dollarAmounts":[{"amount":"DKK 100 million","context":"maximum consideration for share buy-back programme"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T20:33:57.092Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap European life-science instruments","programSize":"DKK 100M / 2.9% of share capital","eventGravity":"routine buyback initiation"}},"durationMs":6877,"modelName":"glm-5.3-flashx"}}